|
| related topics |
| {product, candidate, development} |
| {stock, price, share} |
| {customer, product, revenue} |
| {property, intellectual, protect} |
| {operation, international, foreign} |
| {interest, director, officer} |
| {tax, income, asset} |
| {control, financial, internal} |
| {capital, credit, financial} |
| {acquisition, growth, future} |
|
|
Limited product development activities; our product development efforts may not result in commercial products.
Our operations in China involve significant risk.
We may not be able to continue to operate our business if we are unable to attract additional operating capital.
Our independent registered public accounting firm has included a going concern paragraph in their report on our financial statements.
Our current products cannot be sold in certain countries if we do not obtain and maintain regulatory approval.
USFDA approval for marketing DR-70
Our future prospects will be negatively impacted if we are unsuccessful in pending litigation over the combination immunogene therapy technology.
The value of intangible assets may not be equal to their carrying values.
If our intellectual property positions are challenged, invalidated or circumvented, or if we fail to prevail in future intellectual property litigation, our business could be adversely affected.
We face substantial competition, and others may discover, develop, acquire or commercialize products before or more successfully than we do.
We have limited sales of DR-70
and are reliant on our distributors for sales of our products.
JPI is reliant on its distributors for sales of its products.
We are subject to risks associated with our foreign distributors.
We do not intend to pay dividends on our common stock in the foreseeable future.
If we fail to comply with the rules under the Sarbanes-Oxley Act related to accounting controls and procedures or if material weaknesses or other deficiencies are discovered in our internal accounting procedures, our stock price could decline significantly.
Loss of our listing on the American Stock Exchange could adversely affect the marketability and price of our shares.
Our stock price is volatile, which could adversely affect your investment.
Full 10-K form ▸
|
|
| related documents |
| 838879--4/15/2010--RADIENT_PHARMACEUTICALS_Corp |
| 1017491--3/26/2007--NEXMED_INC |
| 874443--3/22/2007--GENELABS_TECHNOLOGIES_INC_/CA |
| 1038133--2/22/2010--HESKA_CORP |
| 1038133--3/3/2008--HESKA_CORP |
| 1038133--3/16/2009--HESKA_CORP |
| 1066833--3/31/2008--DOV_PHARMACEUTICAL_INC |
| 1038133--3/30/2007--HESKA_CORP |
| 1038133--3/31/2006--HESKA_CORP |
| 1017491--3/12/2008--NEXMED_INC |
| 1017491--3/16/2006--NEXMED_INC |
| 1041024--3/12/2010--ROCKWELL_MEDICAL_TECHNOLOGIES_INC |
| 71478--3/28/2008--LIPID_SCIENCES_INC/ |
| 1096560--3/12/2008--SULPHCO_INC |
| 71478--3/15/2006--LIPID_SCIENCES_INC/ |
| 1298700--4/15/2009--Verdant_Technology_CORP |
| 1041024--3/16/2009--ROCKWELL_MEDICAL_TECHNOLOGIES_INC |
| 1001233--3/1/2007--SANGAMO_BIOSCIENCES_INC |
| 876043--1/16/2007--MEDWAVE_INC |
| 873303--3/16/2007--AVI_BIOPHARMA_INC |
| 873303--3/16/2006--AVI_BIOPHARMA_INC |
| 1030839--2/13/2007--Synovics_Pharmaceuticals |
| 1063665--9/23/2010--CORGENIX_MEDICAL_CORP/CO |
| 849636--3/15/2007--CORTEX_PHARMACEUTICALS_INC/DE/ |
| 1010086--3/13/2008--SIGA_TECHNOLOGIES_INC |
| 907562--3/13/2007--DYAX_CORP |
| 874443--3/31/2006--GENELABS_TECHNOLOGIES_INC_/CA |
| 858803--12/18/2006--AVANIR_PHARMACEUTICALS |
| 926617--4/2/2007--CIPHERGEN_BIOSYSTEMS_INC |
| 1020214--3/11/2010--CERUS_CORP |
|